All News
Filter News
Found 320 articles
-
AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
11/2/2022
AbCellera (Nasdaq: ABCL) announced today that Regeneron has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with AbCellera as part of a multi-target collaboration between the companies, into further preclinical development.
-
AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022
10/11/2022
AbCellera (Nasdaq: ABCL) will announce its third quarter 2022 financial results on Tuesday, November 8, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
-
AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022
10/5/2022
AbCellera (Nasdaq: ABCL) today announced a presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022.
-
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
9/21/2022
AbCellera (Nasdaq: ABCL) today announced it has launched the second phase of its global headquarters expansion by breaking ground on its new facility in Vancouver, Canada.
-
AbCellera Reports Q2 2022 Business Results
8/9/2022
Total revenue of $46 million, compared to $28 million in Q2 2021 Four program starts in the quarter bringing cumulative total to 88, up 47% from Q2 2021 Net loss of per share on a basic and diluted basis compared to per share in Q2 2021
-
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
8/3/2022
AbCellera (Nasdaq: ABCL) and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company.
-
La Jolla Institute for Immunology Acquires the Carterra LSA Platform to Advance State-of-the-Art Immunological and Infectious Disease Research
8/1/2022
Carterra, Inc. and La Jolla Institute for Immunology (LJI) announced today that LJI has acquired a Carterra LSA instrument to enhance its antibody screening and characterization work.
-
Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies
7/27/2022
AbCellera (Nasdaq: ABCL) and Versant Ventures today announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechs.
-
Researchers evaluate just how well therapeutic antibodies and antivirals work against Omicron, Vaxart's oral vaccine shows early promise and hypertension doubles the risk of hospitalization.
-
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
7/12/2022
AbCellera (Nasdaq: ABCL) will announce its second quarter 2022 financial results on Tuesday, August 9, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
-
Life Sciences BC Announces 24th Annual Award Winners
7/7/2022
Life Sciences BC is pleased to announce the recipients of the 24th Annual Life Sciences BC Awards, presented by Farris.
-
Clinical Trials Market Size to Reach Around US$ 95 Billion by 2030
7/5/2022
According to Vision Research Report, the global clinical trials market size is anticipated to reach around US$ 95 billion by 2030. The clinical trials market was valued at US$ 48 billion in 2020 and expanding growth at a CAGR of 7.07% during forecast period 2022 to 2030.
-
There’s quite a bit of movement on the Omicron-specific booster shot and updated supply deals, despite world leaders shifting their attention away from the COVID-19 pandemic.
-
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
6/29/2022
AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab, the second antibody developed through AbCellera’s collaboration with Lilly, for approximately $275 million.
-
Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options
6/29/2022
Eli Lilly and Company announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately $275 million.
-
Clinical Trials Market Size, Share, Trends | Forecast Report 2022-2030
6/1/2022
According to Vision Research Reports, the clinical trials market size is predicted to reach around US$ 75 billion by 2030 and expanding growth at a CAGR of 6% during forecast period 2022 to 2030.
-
Clinical Trials Market Size to Reach US$ 75 Billion by 2030
5/24/2022
According to Vision Research Reports, the clinical trials market size is projected to reach around US$ 75 billion by 2030 from US$ 48 billion in 2020 with a CAGR of 6% during forecast period 2022 to 2030.
-
Invetx Announces Oversubscribed Series B Financing of $60.5 Million to Advance Portfolio of Best-in-Class Veterinary Biotherapeutics
5/10/2022
Invetx, a pioneer in protein-based therapeutics for animal health, today announced that it has raised $60.5 million in an oversubscribed Series B financing.
-
AbCellera Reports Q1 2022 Business Results
5/10/2022
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2022.
-
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
5/3/2022
AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have expanded their strategic multi-target discovery collaboration, which leverages Empirico’s Precision Insights PlatformTM to discover genetically validated drug targets and AbCellera’s technology to identify lead candidate antibodies against those targets.